Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Pataky, Reka ^a,b   Armstrong, Linlea ^a,c,d   Chia, Stephen ^a,d   Coldman, Andrew J ^a   Kim Sing, Charmaine ^a,d   McGillivray, Barbara ^a,c,d   Scott, Jenna ^a   Wilson, Christine M ^a,d,e   Peacock, Stuart ^a,b,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Canadian Centre for Applied Research in Cancer Control   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Screening Mammography Program of British Columbia   (Canada)

Author keywords

BRCA; Breast cancer; Cost effectiveness; MRI; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANADA; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE MUTATION; HEALTH CARE COST; INTERMETHOD COMPARISON; MAMMOGRAPHY; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE IMAGING; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; GENETICS; HUMAN; MUTATION; PROCEDURES;

BREAST NEOPLASMS; CANADA; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; GENES, BRCA1; GENES, BRCA2; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MARKOV CHAINS; MUTATION; QUALITY-ADJUSTED LIFE YEARS;

EID: 84880014746     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-339     Document Type: Article

References (46)

1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130. 10.1086/375033, 1180265, 12677558.
2. Chen SN, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25:1329-1333. 10.1200/JCO.2006.09.1066, 2267287, 17416853.
3. BC Cancer Agency Hereditary Cancer Program Referrals http://www.screeningbc.ca/Hereditary/ForHealthProfessionals/ReferralProcess.htm, BC Cancer Agency.
4. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, et al. Breast cancer risk following bilateral oophorectorny in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 2005, 23:7491-7496. 10.1200/JCO.2004.00.7138, 16234515.
5. Kurian AW, Sigal BM, Plevritis SK. Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers. J Clin Oncol 2009, 28:222-231. 2815712, 19996031.
6. Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MBE, Bartels CCM, Verhoog LC, van den Ouweland AMW, Niermeijer MF, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Eng J Med 2001, 345:159-164.
7. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 2004, 22:1055-1062. 10.1200/JCO.2004.04.188, 14981104.
8. Howard AF, Balneaves LG, Bottorff JL, Rodney P. Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction. Qual Health Res 2011, 21:502-519. 10.1177/1049732310387798, 20980697.
9. Saslow D. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75-89. 10.3322/canjclin.57.2.75, 17392385.
10. Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MMA, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Eng J Med 2004, 351:427-437.
11. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, et al. Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination. JAMA 2004, 292:1317-1325. 10.1001/jama.292.11.1317, 15367553.
12. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. J Clin Oncol 2005, 23:8469-8476. 10.1200/JCO.2004.00.4960, 16293877.
13. Leach MO, Boggis CRM, Dixon AK, Easton DF, Eeles RA, Evans DGR, Gilbert FF, Griebsch I, Hoff RJC, Kessar P, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769-1778.
14. Kriege M, Brekelmans CT, Boetes C, Muller SH, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Rutgers EJ, de Koning HJ, Klijn JG. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer 2006, 106:2318-2326. 10.1002/cncr.21863, 16615112.
15. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007, 43:1905-1917. 10.1016/j.ejca.2007.06.007, 17681781.
16. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008, 148:671-679. 10.7326/0003-4819-148-9-200805060-00007, 18458280.
17. Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, Vergnaghi D, Federico M, Cortesi L, Corcione S, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol 2011, 46:94-105. 10.1097/RLI.0b013e3181f3fcdf, 21139507.
18. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011, 117:3900-3907. 10.1002/cncr.25971, 21365619.
19. Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer 1998, 34:2010-2014. 10.1016/S0959-8049(98)00294-9, 10070302.
20. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA-J Am Med Assoc 2006, 295:2374-2384.
21. Lee JM, McMahon PM, Kong CY, Kopans DB, Ryan PD, Ozanne EM, Halpern EF, Gazelle GS. Cost-effectiveness of Breast MR Imaging and Screen-Film Mammography for Screening BRCA1 Gene Mutation Carriers. Radiology 2010, 254:793-800. 10.1148/radiol.09091086, 2826703, 20177093.
22. Moore S, Shenoy P, Fanucchi L, Tumeh J, Flowers C. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 2009, 9:9. 10.1186/1472-6963-9-9, 2630922, 19144138.
23. Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006, 95:801-810. 10.1038/sj.bjc.6603356, 2360541, 17016484.
24. Norman RPA, Evans DG, Easton DF, Young KC. The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ 2007, 8:137-144. 10.1007/s10198-007-0042-9, 17347845.
25. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'Reilly SE, Olivotto IA. The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort. Cancer 2007, 110:973-979. 10.1002/cncr.22867, 17647245.
26. Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R, Ballard-Barbash R. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 2000, 133:855-863. 10.7326/0003-4819-133-11-200012050-00009, 11103055.
27. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabo A, Apold J, Skaane P, Moller P. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007, 16:367-374. 10.1016/j.breast.2007.01.006, 17317184.
28. Lee JM, Kopans DB, McMahon PM, Halpern EF, Ryan PD, Weinstein MC, Gazelle GS. Breast cancer screening in BRCA1 mutation carriers: Effectiveness of MR imaging - Markov Monte Carlo decision analysis. Radiology 2008, 246:763-771. 10.1148/radiol.2463070224, 18309013.
29. Briggs A, Schulpher M, Claxton K. Decision modelling for health economic evaluation 2006, Oxford: Oxford University Press.
30. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007, 43:238-257. 10.1016/j.ejca.2006.07.019, 17095205.
31. Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S. Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma. PLoS One 2009, 4:e4812. 10.1371/journal.pone.0004812, 2652075, 19277124.
32. BC Medical Services Commission Payment Schedule 2008, http://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/index.html.
33. Screening Mammography Program 2007/2008 Annual Report. Book 2007/2008 Annual Report 2008, City: BC Cancer Agency, Screening Mammography Program.
34. Costing Analysis (CAT) Tool http://www.occp.com/mainPage.htm.
35. Health Employers Association of BC Collective Agreements http://www.heabc.bc.ca/Page20.aspx.
36. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008, 63:962-967. 10.1136/thx.2007.089557, 18621985.
37. Neutel C, Gao R, Gaudette L, Johansen H. Shorter hospital stays for breast cancer. Health Rep 2004, 16:19-31.
38. Schleinitz MD, DePalo D, Blume J, Stein M. Can differences in breast cancer utilities explain disparities in breast cancer care?. J Gen Intern Med 2006, 21:1253-1260. 10.1111/j.1525-1497.2006.00609.x, 1924747, 16961753.
39. Bonomi AE, Boudreau DM, Fishman PA, Ludman E, Mohelnitzky A, Cannon EA, Seger D. Quality of life valuations of mammography screening. Qual Life Res 2008, 17:801-814. 10.1007/s11136-008-9353-2, 18491217.
40. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000, 18:3302-3317.
41. Longson C, Longworth L, Turner K, Dillon A, Barnett D, Culyer T, Littlejohns P, Stevens A. Book Guide to the methods of technology appraisal, Issued: June 2008. 2008, National Institute for Health and Clinical Excellence: City.
42. Byrd LM, Shenton A, Maher ER, Woodward E, Belk R, Lim C, Lalloo F, Howell A, Jayson GC, Evans GD. Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epi Bio Prev 2008, 17:1535-1542.
43. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009, 339:b2587. 10.1136/bmj.b2587, 2714679, 19589821.
44. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of Invasive Breast Cancer Due to Mammography Screening: Results From the Norwegian Screening Program. Ann Intern Med 2012, 156:491-499. 10.7326/0003-4819-156-7-201204030-00005, 22473436.
45. Independent UK Panel on Breast Cancer Screening The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786. Independent UK Panel on Breast Cancer Screening.
46. Moss S. Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 2005, 7:230-234. 10.1186/bcr1314, 1242166, 16168145.